中国实用神经疾病杂志
中國實用神經疾病雜誌
중국실용신경질병잡지
CHINESE JOURNAL OF PRACTICAL NERVOUS DISEASES
2014年
17期
5-6,7
,共3页
周琴%曾艳平%梁静静%周瑜%关景霞%卢祖能
週琴%曾豔平%樑靜靜%週瑜%關景霞%盧祖能
주금%증염평%량정정%주유%관경하%로조능
急性脑梗死%重组组织型先溶酶原激活剂%静脉溶栓
急性腦梗死%重組組織型先溶酶原激活劑%靜脈溶栓
급성뇌경사%중조조직형선용매원격활제%정맥용전
Acute cerebral ischemia%rt-PA%Intravenous thrombolysis
目的:探讨重组组织型纤溶酶原激活剂(rt-PA )静脉溶栓治疗急性脑梗死的安全性及有效性。方法选择发病4.5 h内的急性脑梗死患者45例,采用rt-PA静脉溶栓,评定患者溶栓的安全性,包括症状性出血、血管再闭塞及全身其他部位出血的情况。溶栓后2 h、24 h和7 d分别进行NIHSS评分,评价静脉溶栓治疗的有效性。结果 rt-PA静脉溶栓后发生颅内出血者6例(13.3%),其中症状性颅内出血者3例(6.7%),3例(6.7%)为非症状性颅内出血;4例(8.9%)发生血管再闭塞,其中3例病因为大动脉粥样硬化,1例病因为小血管病。未出现牙龈、消化道出血等。静脉溶栓治疗有效24例(53.3%),其中症状在溶栓后2 h明显改善20例(83.3%),溶栓后24 h症状明显改善4例(16.7%)。静脉溶栓无效15例(33.3%),溶栓后症状加重4例(8.9%),死亡2例(4.4%),均为心源性脑梗死患者。结论超早期rt-PA静脉溶栓是一种有效的治疗脑梗死的方法,且相对安全,对于心源性及NIHSS评分较高的患者,应严格遵守静脉溶栓适应证并充分告知患者或家属相关风险。
目的:探討重組組織型纖溶酶原激活劑(rt-PA )靜脈溶栓治療急性腦梗死的安全性及有效性。方法選擇髮病4.5 h內的急性腦梗死患者45例,採用rt-PA靜脈溶栓,評定患者溶栓的安全性,包括癥狀性齣血、血管再閉塞及全身其他部位齣血的情況。溶栓後2 h、24 h和7 d分彆進行NIHSS評分,評價靜脈溶栓治療的有效性。結果 rt-PA靜脈溶栓後髮生顱內齣血者6例(13.3%),其中癥狀性顱內齣血者3例(6.7%),3例(6.7%)為非癥狀性顱內齣血;4例(8.9%)髮生血管再閉塞,其中3例病因為大動脈粥樣硬化,1例病因為小血管病。未齣現牙齦、消化道齣血等。靜脈溶栓治療有效24例(53.3%),其中癥狀在溶栓後2 h明顯改善20例(83.3%),溶栓後24 h癥狀明顯改善4例(16.7%)。靜脈溶栓無效15例(33.3%),溶栓後癥狀加重4例(8.9%),死亡2例(4.4%),均為心源性腦梗死患者。結論超早期rt-PA靜脈溶栓是一種有效的治療腦梗死的方法,且相對安全,對于心源性及NIHSS評分較高的患者,應嚴格遵守靜脈溶栓適應證併充分告知患者或傢屬相關風險。
목적:탐토중조조직형섬용매원격활제(rt-PA )정맥용전치료급성뇌경사적안전성급유효성。방법선택발병4.5 h내적급성뇌경사환자45례,채용rt-PA정맥용전,평정환자용전적안전성,포괄증상성출혈、혈관재폐새급전신기타부위출혈적정황。용전후2 h、24 h화7 d분별진행NIHSS평분,평개정맥용전치료적유효성。결과 rt-PA정맥용전후발생로내출혈자6례(13.3%),기중증상성로내출혈자3례(6.7%),3례(6.7%)위비증상성로내출혈;4례(8.9%)발생혈관재폐새,기중3례병인위대동맥죽양경화,1례병인위소혈관병。미출현아간、소화도출혈등。정맥용전치료유효24례(53.3%),기중증상재용전후2 h명현개선20례(83.3%),용전후24 h증상명현개선4례(16.7%)。정맥용전무효15례(33.3%),용전후증상가중4례(8.9%),사망2례(4.4%),균위심원성뇌경사환자。결론초조기rt-PA정맥용전시일충유효적치료뇌경사적방법,차상대안전,대우심원성급NIHSS평분교고적환자,응엄격준수정맥용전괄응증병충분고지환자혹가속상관풍험。
Objective To observe the efficiency and safety of the intravenous thrombolysis using recombinant plasminogen activator (rt-PA) for acute cerebral ischemia. Methods 45 acute cerebral ischemia patients within 4.5h of the onset of stroke were included. They were all given rt-PA for intravenous thrombolysis. The safety of the therapy was assessed through the rate of the secondary intracerebral hemorrhage ,the reocclusion ,and the abnormal bleeding. The efficiency was assessed through the NIHSS scores at the time of 2h ,24h and 7d after the therapy. Results There were 6 patients (13.3% ) who had secondary intracerebral hemorrhage. Among them ,3 patients (6.7% ) had symptomatic intracranial hemorrhage ,other 3 pa-tients (6.7% ) had non-symptomatic intracranial hemorrhage. Four patients (8.9% ) had reocclusion ,among these patients , three were atherosclerosis and the other one was small vessel disease. No patients had gingival or gastrointestinal bleeding. 24 patients (53.3% ) benefited from the thrombolytic therapy. Among them ,the symptoms of 20 patients significantly improved in 2 h after the therapy ,and the symptoms of the other 4 patients obviously improved in 24h after the therapy. Fifteen patients (33.3% ) had no changes ,4 patients (8.9% ) had deterioration ,and 2 patients (4.4% ) died.Conclusion Intravenous throm-bolysis with rt-PA is an effective method for the treatment of cerebral infarction. It is relatively safe ,however ,thrombolytic therapy should be strictly compliance with the indications for patients with cardiogenic cerebral infarction or higher NIHSS score ,and the associated risks should be fully informed to the patients or their families.